Ameritas Advisory Services LLC Trims Holdings in Eli Lilly and Company $LLY

Key Points

• Ameritas Advisory Services LLC has reduced its holdings in Eli Lilly and Company by 42.4%, now owning 4,306 shares valued at approximately $3.36 million.
• Eli Lilly reported strong earnings with $6.31 EPS, exceeding analysts' expectations, and a revenue of $15.56 billion, marking a 37.6% year-over-year increase.
• Recent changes in analyst ratings include DZ Bank upgrading Eli Lilly from "hold" to "strong-buy" and UBS lowering its price target from $1,050 to $895 while maintaining a "buy" rating.

Ameritas Advisory Services LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 42.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,306 shares of the company's stock after selling 3,169 shares during the quarter. Ameritas Advisory Services LLC's holdings in Eli Lilly and Company were worth $3,357,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. PNC Financial Services Group Inc. grew its position in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after buying an additional 50,002,551 shares in the last quarter. Vanguard Group Inc. grew its position in Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after buying an additional 4,975,395 shares in the last quarter. Wellington Management Group LLP lifted its stake in Eli Lilly and Company by 0.6% during the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company's stock worth $10,495,261,000 after purchasing an additional 81,587 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Eli Lilly and Company by 13.3% during the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company's stock worth $4,808,443,000 after purchasing an additional 682,203 shares during the last quarter. Finally, Nuveen LLC bought a new stake in Eli Lilly and Company during the first quarter worth about $4,613,912,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.6%

LLY stock opened at $820.69 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The business's 50 day moving average price is $734.03 and its two-hundred day moving average price is $766.34. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $776.75 billion, a price-to-earnings ratio of 53.64, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the subject of a number of recent research reports. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. UBS Group lowered their target price on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a research note on Friday, August 8th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price target (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Morgan Stanley reaffirmed an "overweight" rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average price target of $939.61.

Insider Buying and Selling

In related news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gabrielle Sulzberger purchased 117 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.